Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(IDRA, CRWE, BPL, MJGCF, AAP) Stock Report from Stock-PR.com

|Includes: AAP, BPL, Idera Pharmaceuticals, Inc. (IDRA)

Stock-PR Reporting

stockpr_logo-site

 

FREE Daily Stock Alerts From Stock-PR.com

chartstockalert

http://crweselect.com/img/stwidra.png

http://crweselect.com/img/idra.jpg Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

IDRA applies its proprietary Toll-like Receptor (NYSEMKT:TLR) drug discovery platform to create immunomodulatory drug candidates. The Company’s TLR-targeted candidates are being developed to treat autoimmune and inflammatory diseases, cancer, and for use as vaccine adjuvants. Additionally, the Company is advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes.

IDRA recently announced it has raised $9.5 million in a convertible preferred stock offering. In the offering, the Company issued and sold 1,124,260 shares of its convertible preferred stock convertible into 5,621,300 shares of common stock and warrants to purchase 2,810,650 shares of common stock. Each share of convertible preferred stock is convertible into five shares of common stock at a conversion price of $1.6275 per share and warrants are exercisable at $1.6275 per share. The purchase price represents a five percent premium to the closing price of Idera’s common stock on Thursday, November 3rd, 2011.

IDRA intends to use the net proceeds from the transaction for general corporate purposes, including continuing to fund development of Toll-like Receptor (TLR) targeted candidates in its autoimmune and inflammatory disease program and its gene-silencing oligonucleotide (GSO) technology.

For more information about IDRA please visit http://www.iderapharma.com

Read full article at: http://stock-pr.com/?p=20628

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a media-advertisement and newswire company.Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

http://stock-pr.com/img/stock-pr_buscard.jpg